==========
Sequence Listing was accepted.
See attached Validation Report.
If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).
Reviewer: Durreshwar Anjum
Timestamp: [year=2009; month=2; day=18; hr=13; min=52; sec=48; ms=19;]
==========

Validated By CRFValidator v 1.0.3

Application No: 10518914 Version No: 2.0

Input Set:

Output Set:

Started: 2009-01-30 14:44:43.489
Finished: 2009-01-30 14:44:47.754
Elapsed: 0 hr(s) 0 min(s) 4 sec(s) 265 ms
Total Warnings: 12
Total Errors: 36
No. of SeqIDs Defined: 12
Actual SeqID Count: 12

Error code		Error Description
W	213	Artificial or Unknown found in <213> in SEQ ID (1)
E	257	Invalid sequence data feature in <221> in SEQ ID (1)
E	257	Invalid sequence data feature in <221> in SEQ ID (1)
E	257	Invalid sequence data feature in <221> in SEQ ID (1)
E	257	Invalid sequence data feature in <221> in SEQ ID (1)
W	213	Artificial or Unknown found in <213> in SEQ ID (2)
E	257	Invalid sequence data feature in <221> in SEQ ID (2)
E	257	Invalid sequence data feature in <221> in SEQ ID (2)
E	257	Invalid sequence data feature in <221> in SEQ ID (2)
E	257	Invalid sequence data feature in <221> in SEQ ID (2)
E	257	Invalid sequence data feature in <221> in SEQ ID (2)
E	257	Invalid sequence data feature in <221> in SEQ ID (2)
E	257	Invalid sequence data feature in <221> in SEQ ID (2)
E	257	Invalid sequence data feature in <221> in SEQ ID (2)
W	213	Artificial or Unknown found in <213> in SEQ ID (3)
E	257	Invalid sequence data feature in <221> in SEQ ID (3)
E	257	Invalid sequence data feature in <221> in SEQ ID (3)
E	257	Invalid sequence data feature in <221> in SEQ ID (3)
W	213	Artificial or Unknown found in <213> in SEQ ID (4)
E	257	Invalid sequence data feature in <221> in SEQ ID (4)

Input Set:

Output Set:

Started: 2009-01-30 14:44:43.489
Finished: 2009-01-30 14:44:47.754
Elapsed: 0 hr(s) 0 min(s) 4 sec(s) 265 ms
Total Warnings: 12
Total Errors: 36
No. of SeqIDs Defined: 12
Actual SeqID Count: 12

Error code	Error Description
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
E 257	Invalid sequence data feature in <221> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
E 257	Invalid sequence data feature in <221> in SEQ ID (6) This error has occured more than 20 times, will not be displayed
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)

SEQUENCE LISTING

<110> YAMAMOTO, KAZUMICHI
SAITO, KAZUHIRO
HOSHINO, TETSUO

<120> PROCESS FOR PRODUCING SUSTAINED-RELEASE COMPOSITION

<130> 074129-0516

<140> 10518914
<141> 2009-01-30

<150> PCT/JP03/07950
<151> 2003-06-24

<150> JP 2002-185352
<151> 2002-06-25

<160> 12

<170> PatentIn version 3.5

<210> 1
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<221> MOD_RES
<222> (6)..(6)
<223> DLeu, DAla, DTrp, DSer(tBu), D2Nal or DHis(ImBzl)

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Pro or Pro-NH-C2H5

<220>
<221> MOD_RES
<222> (10)..(10)
<223> Gly-NH2 or not present

<220>
<223> see specification as filed for detailed description of substitutions and preferred embodiments

<400> 1
Pro His Trp Ser Tyr Xaa Leu Arg Pro Gly
1   5   10

<210> 2
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<223> N-term may or may not be acetylated

<220>
<221> MOD_RES
<222> (1)..(1)
<223> N(4H2-furoyl)Gly or absent

<220>
<221> MOD_RES
<222> (2)..(2)
<223> D2Nal

<220>
<221> MOD_RES
<222> (3)..(3)
<223> D4ClPhe

<220>
<221> MOD_RES
<222> (4)..(4)
<223> D3Pal

<220>
<221> MOD_RES
<222> (6)..(6)
<223> NMeTyr, Tyr, Aph(Atz) or NMeAph(Atz)

<220>
<221> MOD_RES
<222> (7)..(7)
<223> DLys(Nic), DCit, DLys(AzaglyNic), DLys(AzaglyFur),
      DhArg(Et2), DAph(Atz) or DhCi

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Lys(Nisp), Arg or hArg(Et2)

<220>
<221> MOD_RES

<222> (11)..(11)
<223> DAla

<220>
<223> C-term amidated

<220>
<223> see specification as filed for detailed description of
substitutions and preferred embodiments

<400> 2
Gly Xaa Phe Xaa Ser Xaa Xaa Leu Xaa Pro Ala
1 5 10

<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<221> MOD_RES
<222> (6)..(6)
<223> DLeu

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Pro-NH-C2H5

<400> 3
Pro His Trp Ser Tyr Leu Leu Arg Pro
1 5

<210> 4
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES

<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Ser(tBu)

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Pro-NH-CH2-CH3

<400> 4
Pro His Trp Ser Tyr Ser Leu Arg Pro
1   5

<210> 5
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<223> C-term amidated

<400> 5
Pro His Trp Ser Tyr Trp Leu Arg Pro Gly
1   5   10

<210> 6
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 5-oxo-Pro

<220>

<221> MOD_RES
<222> (6)..(6)
<223> D2Nal

<220>
<223> C-term amidated

<400> 6
Pro His Trp Ser Tyr Xaa Leu Arg Pro Gly
1   5   10

<210> 7
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<221> MOD_RES
<222> (6)..(6)
<223> DHis(ImBzl)

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Pro-NH-CH2-CH3

<400> 7
Pro His Trp Ser Tyr His Leu Arg Pro
1   5

<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Pro-NH-CH2-CH2-NH2

<400> 8
Pro His Trp Ser Tyr Trp Leu Arg Pro
1   5

<210> 9
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2MeTrp

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Pro-NH-CH2-CH3

<400> 9
Pro His Trp Ser Tyr Trp Leu Arg Pro
1   5

<210> 10
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<223> C-term amidated

<400> 10
Pro His Trp Ser Tyr Gly Leu Arg Pro Gly
1   5   10

<210> 11
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Ser(tBu)

<220>
<221> MOD_RES
<222> (9)..(9)
<223> Pro-NH-NH-CO-NH2

<400> 11
Pro His Trp Ser Tyr Ser Leu Arg Pro
1   5

<210> 12
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<221> MOD_RES
<222> (6)..(6)
<223> D3MeVal

<220>

<221> MOD_RES
<222> (9)..(9)
<223> Pro-NH-C2H5

<400> 12
Pro His Trp Ser Tyr Val Leu Arg Pro
1   5